Roeslin N, Lang J M, Morand G, Wihlm J M, Witz J P
Cancer Immunol Immunother. 1982;13(3):174-5. doi: 10.1007/BF00205383.
Patients with resectable squamous cell carcinoma were randomly allocated after surgery to receive either no further treatment (57 patients) or a single intrapleural injection of BCG (61 patients). No significant improvement in survival was observed in patients treated with BCG, even when their disease was staged as N0. There was a slight trend for the recurrence rate to be lower in patients classed as N0, but this was not significant.
可切除的鳞状细胞癌患者在手术后被随机分配,要么不接受进一步治疗(57例患者),要么接受单次胸膜内注射卡介苗(61例患者)。即使疾病分期为N0,接受卡介苗治疗的患者在生存率方面也未观察到显著改善。被归类为N0的患者复发率有轻微降低趋势,但并不显著。